Study Shows Why Internal Scars Won't Stop Growing

Scientists have discovered new compound that halts some fibrotic diseases. Fibrosis accounts for up to 40 percent of all global deaths and human fibrotic cells reveal immune abnormality.

Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis -- the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.

Skin Substitutes - Types, Advantages, Disadvantages
Find the facts of skin substitutes including types, advantages and disadvantages of skin substitutes.

‘Northwestern Medicine scientists have discovered a delinquent gang of molecules that continually shouted at an immune receptor - the antennae on the cell -- to produce scar tissue instead of quieting down and allowing the scar tissue to go back to sleep.’

Tweet it Now

Fibrosis - a progressive scarring and hardening of internal organs - is estimated to cause 35 to 40 percent of deaths in the world. Fibrotic diseases include diabetic kidney fibrosis, alcoholic liver cirrhosis, hepatitis C, pulmonary fibrosis and nonalcoholic fatty liver disease, which may lead to fibrosis of the liver, the leading cause of liver transplant.

Scientists collaborated with a University of Colorado researcher who used crystallography and computer modeling to predict a molecule that could block the receptor that leads to the uncontrolled scarring. When they tested the molecule, T53, in three different mouse models of fibrosis, the abnormality was significantly reversed.

"Our study opens a new door into fibrosis by looking at it as an aberrant innate immune response and suggesting a novel approach to treat it," said senior author Dr. John Varga, director of the Northwestern Scleroderma Program and the John and Nancy Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg School of Medicine.

New Plaster to Protect Wounds from Infection
Nature creates its own plaster to try and prevent bacteria and other micro-organisms from penetrating open wounds.

The paper is published in the Journal of Clinical Investigation Insight.

"The leading cause of liver failure in western world is obesity and that's because of liver fibrosis," Varga said. "In the U.S., many of these diseases are lifestyle or age dependent. As we get fatter or older, they get worse."

New Regenerative Bandage for Faster Diabetic Wound Healing
New regenerative bandage can enhance rapid wound healing in patients with diabetes without using drugs. Simple scrape, sore or untreated scratch can turn into an open wound which can potentially lead to limb amputation in most diabetic patients.

Most fibrotic disease likely begins as normal repair of an injury, scientists said. "But if the immune system produces too much of an initial scar, it can't go back to normal," Varga said. "You have an unhealed scar that keeps growing and can wipe out the entire organ."

Not everyone's fibrosis is caused by the same abnormality, Varga said. If the compound, T53, is eventually developed into an approved drug, it would be targeted to patients with the specific genetic signature identified in the study.

New Dressing Material to Treat Diabetic Wounds Developed by IIT Madras
A novel wound dressing material developed aids in healing wounds faster in either normal people or in diabetic patients. The material is much cheaper than all the other materials that are currently available.

"There is an emerging direction for treating fibrosis with precision medicine," said first author Swati Bhattacharyya, research associate professor of medicine in rheumatology and scientific director of the Scleroderma Research Laboratory at Feinberg. "Some people live with fibrotic disease for 30 years while others die in two years. We need to identify the rapid progressors from the slow progressors. That's where precision medicine becomes really critical."

"The results of this study are encouraging," Varga said. "We are not saying this compound is ready to be a drug. It's an initial compound that would need to be developed and tweaked. It would need significant funding to go to the next step."

Varga has spent more than a decade researching the cause and treatment of scleroderma, a type of fibrosis that simultaneously affects multiple organs. He directs the Northwestern Scleroderma Program, a clinical and research effort that follows 1,500 patients with scleroderma.

Source-Eurekalert